|
|
|
|
LEADER |
00000cam a2200000 a 4500 |
001 |
SCIDIR_ocn820345446 |
003 |
OCoLC |
005 |
20231117044813.0 |
006 |
m o d |
007 |
cr cnu---unuuu |
008 |
121205s1991 xx o 000 0 eng d |
040 |
|
|
|a OPELS
|b eng
|e pn
|c OPELS
|d IDEBK
|d OCLCF
|d UIU
|d OCLCQ
|d LEAUB
|d OCLCQ
|d OCLCO
|d OCLCQ
|
020 |
|
|
|z 0123707250
|
020 |
|
|
|z 9780123707253
|
035 |
|
|
|a (OCoLC)820345446
|
050 |
|
4 |
|a RM282.I44
|b I46 1991
|
082 |
0 |
4 |
|a 615.3/7
|2 23
|
245 |
0 |
0 |
|a Immunotherapy with intravenous immunoglobulins /
|c edited by Paul Imbach.
|
260 |
|
|
|a [Place of publication not identified] :
|b Academic Press,
|c 1991.
|
300 |
|
|
|a 1 online resource
|
336 |
|
|
|a text
|b txt
|2 rdacontent
|
337 |
|
|
|a computer
|b c
|2 rdamedia
|
338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
520 |
|
|
|a The use of intravenous human antibodies in the treatment of primary immunodeficiencies is well recognized. However, it is now evident that they also have therapeutic potential for a wide range of other clinical disorders. This book describes the use of human antibodies in the management of secondary (virus-induced) immunodeficiencies, neonatal and perinatal infections, and autoimmunity. Insight into their mechanism of action is also provided.
|
588 |
0 |
|
|a Publisher supplied information; title not viewed.
|
650 |
|
0 |
|a Immunoglobulins
|x Therapeutic use.
|
650 |
|
0 |
|a Immunoglobulins.
|
650 |
|
0 |
|a Immunotherapy.
|
650 |
|
2 |
|a Immunotherapy
|0 (DNLM)D007167
|
650 |
|
6 |
|a Immunoth�erapie.
|0 (CaQQLa)201-0067406
|
650 |
|
7 |
|a Immunoglobulins.
|2 fast
|0 (OCoLC)fst00967961
|
650 |
|
7 |
|a Immunoglobulins
|x Therapeutic use.
|2 fast
|0 (OCoLC)fst00967968
|
650 |
|
7 |
|a Immunotherapy.
|2 fast
|0 (OCoLC)fst00968044
|
700 |
1 |
|
|a Imbach, Paul.
|
856 |
4 |
0 |
|u https://sciencedirect.uam.elogim.com/science/book/9780123707253
|z Texto completo
|